In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells

Immunotherapy

Volumn 6, Issue 1, 2014, Pages 43-49

  Tahmasebi, Fathollah ^a   Kazemi, Tohid ^b,c   Amiri, Mohammad Mehdi ^c   Khoshnoodi, Jalal ^c   Mahmoudian, Jafar ^a   Bayat, Ali Ahmad ^a   Jeddi Tehrani, Mahmood ^a   Rabbani, Hodjatallah ^a   Shokri, Fazel ^a,c  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

breast cancer; HER2; monoclonal antibodies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84896501972     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.156     Document Type: Article

References (32)

1. Kazemi T, Tahmasebi F, Bayat AA et al. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma (Larchmt) 30(4), 347-353 (2011).
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000).
3. Shen G, Huang H, Zhang A et al. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with paclitaxel or trastuzumab in breast and ovarian cancer xenograft models. Cancer Immunol. Immunother. 60(3), 339-348 (2011).
4. Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol. Immunother. 59(9), 1295-1312 (2010).
5. Yarden Y, Ullrich A. Molecular analysis of signal transduction by growth factors. Biochemistry 27(9), 3113-3119 (1988).
6. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA 80(5), 1337-1341 (1983).
7. Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
9. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 26(25), 3637-3643 (2007).
10. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19), 4265-4274 (2005).
11. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 21(15), 2889-2895 (2003).
12. Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-alpha. BMC Cancer 12, 450 (2012).
13. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
14. Traynor K. FDA approves pertuzumab for breast cancer. Am. J. Health Syst. Pharm. 69(14), 1178 (2012).
15. Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012, 415170 (2012).
16. Provides an up-to-date overview of novel HER2-directed therapies in clinical development.
17. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9(3), 1165-1172 (1989).
18. Kita Y, Tseng J, Horan T et al. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem. Biophys. Res. Commun. 226(1), 59-69 (1996).
19. Faratian D, Zweemer AJ, Nagumo Y et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin. Cancer Res. 17(13), 4451-4461 (2011).
20. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl Acad. Sci. USA 92(8), 3353-3357 (1995).
21. Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 166(8), 5271-5278 (2001).
22. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl Acad. Sci. USA 88(19), 8691-8695 (1991).
23. Sims AH, Zweemer AJ, Nagumo Y et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br. J. Cancer 106(11), 1779-1789 (2012).
24. nn Comprehensive study of the molecular response to trastuzumab, pertuzumab and combined therapy in vivo.
25. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68(6), 1140-1145 (1993).
26. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/ HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl Acad. Sci. USA 106(9), 3294-3299 (2009).
27. Friedman LM, Rinon A, Schechter B et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102(6), 1915-1920 (2005).
28. Several mechanisms are proposed for combinatorial effects of monocolonal antibodies that are more effective compared with a single monoclonal antibody in inhibiting HER2 signaling in vitro and tumorigenesis in animals.
29. Yip YL, Novotny J, Edwards M, Ward RL. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: implications for receptor signalling. Int. J. Cancer 104(3), 303-309 (2003).
30. Lu H, Ladd J, Feng Z et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev. Res. (Phila.) 5(8), 1036-1043 (2012).
31. Helguera G, Dela Cruz JS, Lowe C et al. Vaccination with novel combinations of antiHER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/ neu expressing tumors. Vaccine 24(3), 304-316 (2006).
32. Dela Cruz JS, Lau SY, Ramirez EM et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21(13-14), 1317-1326 (2003).